While some proposed changes to how the US Food and Drug Administration regulates in vitro clinical tests will help to better protect patients, several provisions could undermine the agency’s efforts and need further clarification, according to The Pew Charitable Trusts.
In a letter to Senate Health, Education, Labor and Pensions (HELP) Committee chair Patty Murray, D-WA, and ranking member...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?